Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia

International Journal of Clinical Practice

Volumn 58, Issue 7, 2004, Pages 653-658

  Ballantyne, Christie M ^a   Lipka, L J ^b   Sager, P T ^b   Strony, J ^b   Alizadeh, J ^b   Suresh, R ^b   Veltri, E P ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol; Drugs; Hypercholesterolaemia; Lipoproteins; Trials

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CHOLESTATIC HEPATITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDUCATION PROGRAM; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; INCIDENCE; LABORATORY TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; MYOPATHY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 4344704320     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00278.x     Document Type: Article

References (17)

1. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-41.
2. Van Heek M, Farley C, Compton DS et al. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 2003; 138: 1459-64.
3. Van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001; 415: 79-84.
4. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999; 65: 1329-37.
5. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
6. Stein EA. An investigative look: selective cholesterol absorption inhibitors - embarking on a new standard of care. Am J Manag Care 2002; 8: S36-S39.
7. Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418-24.
8. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hyperc holesterolemia. J Am Coll Cardiol 2002; 40: 2125-34.
9. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double- blind trial. Circulation 2003; 107: 2409-15.
10. Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-28.
11. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
12. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
16. Gagne C, Masana L, Gumbiner B et al. Long-term safety and efficacy of ezetimibe added to ongoing simvastatin treatment. Atherosclerosis 2003: Suppl. 4 [Abstract];
17. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.